Survodutide is a synthetic, acylated peptide designed for once-weekly subcutaneous administration. Its novel mechanism of action as a dual agonist allows it to target two key metabolic pathways simultaneously.

• GLP-1 Receptor Agonism: Similar to other incretin mimetics, activating the GLP-1 receptor helps regulate appetite, increase feelings of satiety, and control blood sugar levels.

• Glucagon Receptor Agonism: This component is believed to increase energy expenditure and promote the breakdown of fat (lipolysis), particularly targeting fat accumulation in the liver.

By combining these two actions, Survodutide is being studied for its robust effects on both weight reduction and the improvement of liver health. Clinical trials have investigated its potential to significantly reduce body weight and to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

• CAS Number: 2805997-46-8

• Molecular Formula: C₁₉₂H₂₈₉N₄₇O₆₁

• Molecular Weight: 4231.62 g/mol

• Synonyms: BI 456906